SciClone Pharmaceuticals, Inc. (SCLN)

[surf1944]

7:00AM SciClone Pharma and Sigma-Tau announce final data from clinical trial of ZADAXIN as H1N1 vaccine enhancer (SCLN) 2.74 : Co announced final results from a clinical study evaluating the potential of ZADAXIN to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine, Focetria from Novartis (NVS). Final data from the study showed that, when evaluated 84 days following vaccination, 60% of patients in the high-dose ZADAXIN arm achieved seroconversion, compared to 55% of patients in the vaccine-only arm of the study.